One aspect of the cannabis industry experts have advised investors about seeing major growth alongside the cannabis market is the ancillary and side services taking advantage of the legalization movement all across the world.
To provide a little bit of perspective on this, the Investing News Network (INN) had the opportunity to talk with Sean Dollinger, president and CEO of Namaste Technologies (CSE:N; OTC:NXTTF) about the company’s recently launched app-based platform NamasteMD for patients in Canada.
Namaste started by offering vaporizers and smoking accessories across the globe. Dollinger told INN they identified a correlation between people buying these products and cannabis users.
“Our whole idea is about being a platform, so LPs place their products on our platform; whereas we are the technology behind it,” Dollinger said.
Namaste previously earned some recognition in the industry when Aurora Cannabis (TSX:ACB; OTC:ACBFF) announced a hardware investment deal last year, which kicked off what has been a fruitful relationship between the companies.
The services of NamasteMD
Through a mobile app cannabis patients can input their data and be connected to a physician who offers cannabis as medicine. Then in the same app, the patient can have access to a catalogue of products from almost all LPs.
According to Dollinger Namaste has signed a service agreement with all the “top LPs” and are almost done signing every single LP in Canada.
The app has favorable reviews on Apple’s (NASDAQ:AAPL) own App Store and currently holds a five star rating based on 171 user reviews.
“We already have about 450 patients, and in March our target is to hit 1,500 patients… we’re aiming to have over 2,000 patients by the end of March,” Dollinger told INN, adding the company’s estimations for its year-end user base is currently 5,500 patients.
With all of the data Namaste will be collecting, which Dollinger told INN has not been decided,exactly, how to best monetize it, the company has plenty of options available on the consumer trends it will catalogue once more patients are using its service.
Namaste’s data collecting will also be enhanced by the option for patients to download a smartwatch app. Dollinger said Namaste will be able to give users specific information on the effects of the products available to patients in its service.
As part of the company’s most recent sales update to investors, Namaste reported a 146 percent unaudited net revenue increase compared to the same month last year. The company said it expects these year-on-year growth marks to continue thanks to the complete legalization of cannabis in Canada this year.
“Our ability to provide patients with an all-inclusive e-commerce marketplace of cannabis products and services in the near term should serve to significantly increase our market share moving forward,” Dollinger said in Namaste’s statement.
Dollinger also told INN Namaste is in the works to upgrade its common stock both in Canada and the US. Namaste wants to move up to the TSX Venture exchange and move its stock from the OTCQB Best Market onto the Nasdaq.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.